The European Medicines Agency (EMA) on Wednesday recommended authorization of GSK s Arexvy vaccine for respiratory syncytial virus in adults aged 60 and older.
A panel of outside advisers to the US health regulator backed GSK s respiratory syncytial virus vaccine, setting it up for a race with rival Pfizer to become the first approved US shot against the disease.
A panel of outside advisers to the US health regulator recommended Pfizer Inc s respiratory syncytial virus vaccine, bringing it closer to becoming one of the first approved RSV shots for older adults in the United States.
According to survey results from the Kaiser Family Foundation, 27% of households reported someone sick with the flu. COVID-19 infections affected 15% of households, and 10% reported an RSV infection.